Brøsen K, de Morais S M, Meyer U A, Goldstein J A
Department of Clinical Pharmacology, Institute of Medical Biology, Odense University, Denmark.
Pharmacogenetics. 1995 Oct;5(5):312-7. doi: 10.1097/00008571-199510000-00007.
It has recently been shown that the most common mutation (named m1) in both Caucasian and Japanese poor metabolizers (PM) of S-mephenytoin is a single base pair mutation (G-->A) in exon 5 of the CYP2C19 gene. In Japanese, a second defective allele of CYP2C19 named m2 consists of a G-->A mutation in exon 4. In the present study, we have investigated the inheritance of the CYP2C19 wild type allele (wt) and the two defective alleles (m1 and m2) in families of 11 Danish PM probands. The study was carried out for two principal reasons. First, we wanted to confirm the autosomal recessive inheritance of the defective alleles, and second, we wanted to examine the specificity and sensitivity of the CYP2C19 genotyping test. Individuals were phenotyped by measuring the ratio of S/R mephenytoin excreted in the urine after administration of mephenytoin, and genotyping was carried out by a PCR-based DNA amplification procedure. The genotypes of nine of the 11 probands were consistent with their phenotypes. Eight were homozygous m1/m1, and one was heterozygous m1/m2. The genotypes of two putative PM probands (wt/m1) were not consistent with their phenotypes. On the basis of extended phenotyping (additional late urine collections (24-36 h) and acidification of urine), one of these could probably be reclassified as an extensive metabolizer (EM) while the other was considered to be a true PM. This suggests the presence of an additional unknown mutant allele in the latter. Seven of the 41 phenotyped relatives in the 11 families were phenotyped as PMs, and with the exception of the father of family 10, their genotypes (m1/m1) were consistent with their phenotypes. Extended phenotyping (acidification of urine) suggested that the father of family 10 in fact is an EM and hence that his genotype (wt/m1) is concordant with his phenotype. Thus, the specificity of genotyping tests for PM was 100%, while the sensitivity was 15/16 or 94%. Our study provides unequivocal evidence for autosomal recessive inheritance of the PM trait.
最近研究表明,在白种人和日本S-美芬妥因慢代谢者(PM)中最常见的突变(命名为m1)是CYP2C19基因第5外显子中的单碱基对突变(G→A)。在日本人中,CYP2C19的第二个缺陷等位基因m2由第4外显子中的G→A突变组成。在本研究中,我们调查了11名丹麦PM先证者家庭中CYP2C19野生型等位基因(wt)和两个缺陷等位基因(m1和m2)的遗传情况。进行这项研究主要有两个原因。第一,我们想证实缺陷等位基因的常染色体隐性遗传;第二,我们想检测CYP2C19基因分型检测的特异性和敏感性。通过测量服用美芬妥因后尿中排泄的S/ R美芬妥因比值对个体进行表型分析,并通过基于PCR的DNA扩增程序进行基因分型。11名先证者中有9人的基因型与其表型一致。8人是m1/m1纯合子,1人是m1/m2杂合子。两名推定的PM先证者(wt/m1)的基因型与其表型不一致。根据扩展表型分析(额外收集晚期尿液(24 - 36小时)并酸化尿液),其中一人可能可重新分类为快代谢者(EM),而另一人被认为是真正的PM。这表明后者存在另一个未知的突变等位基因。11个家庭中41名进行了表型分析的亲属中有7人被表型分析为PM,除了1个家庭的父亲外,他们的基因型(m1/m1)与其表型一致。扩展表型分析(酸化尿液)表明10号家庭的父亲实际上是EM,因此他的基因型(wt/m1)与其表型一致。因此,PM基因分型检测的特异性为100%,而敏感性为15/16或94%。我们的研究为PM性状的常染色体隐性遗传提供了明确证据。